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Stem cell therapy has emerged as a promising therapeutic strategy for inflammatory bowel
diseases (IBDs). Currently, stem cell therapy is not part of the standard of care and is usually only
performed as a part of clinical trials. In this review, clinical results, proposed underlying mechanisms,
and future research directions will be discussed.
Recent findings
Administration of mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) has been
evaluated for IBD treatment over the past years. MSC therapy is being explored as a treatment
option for fistulizing Crohn’s disease and for luminal Crohn’s disease. It is shown to be well
tolerated, but results on efficacy are inconsistent. HSC transplantation seems to be very effective, but
serious adverse events are common. Therefore, future research should focus on improving efficacy of
MSC therapy, and on improvement of safety of HSC therapy.
Summary
Both MSC and HSC therapy offer clinical potential, but currently are not routinely used for
IBD treatment. MSC therapy seems well tolerated but results on efficacy are conflicting.
HSC transplantation is shown to be effective but safety concerns remain. Nonetheless,
for severe refractory IBD cases, stem cell therapy could well become the next-generation
treatment option.
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Stem cell therapy is a field that has developed
considerably in the past years. Stem cells have
the capacity to generate different types of daughter
cells, and thus have been proposed as a valuable
tool for regeneration of damaged tissue. Hemato-
poietic stem cells (HSCs) are capable of regenerat-
ing immune cells [1], which creates the theoretical
possibility to create a new immune system without
autoimmunity in inflammatory bowel disease
(IBD) patients [2
&&
]. Mesenchymal stem cells
(MSCs) can differentiate into different mesen-
chymal cell lines and also exert immunosuppres-
sive functions, which might be beneficial in IBD
[3
&
]. Several other adult stem cells have been
explored in preclinical settings as well. In this
article, the emphasis will be on HSCs and MSCs
because those have been already used in clinical
settings.iams & Wilkins. UnauthoPATHOGENESIS OF INFLAMMATORY
BOWEL DISEASES
The pathogenesis of IBD remains largely unclear
even though considerable advances in this field
have been made. IBD is thought to be caused by
a dysregulated immune response against commu-
nal, nonpathogenic bowel antigens in a geneti-
cally susceptible individual. Both genetic andrized reproduction of this article is prohibited.
Volume 29  Number 4  July 2013
KEY POINTS
 Both HSCT and MSC therapy are currently being
evaluated for IBD treatment in trial settings.
 HSCT offers the opportunity to generate a new immune
system free of autoimmunity. Currently, the main
limitation of HSCT is safety, but efficacy has been
shown consistently.
 MSCs have tissue regenerative properties and exert
immunosuppressive functions, theoretically making them
a valuable tool for IBD treatment. MSC therapy is well
tolerated, but results on efficacy have been inconsistent.
Further research needs to be aimed at improving MSC
efficacy by optimizing isolation, expansion and
stimulation procedures of MSCs.
Stem cell therapy in inflammatory bowel disease van Deen et al.environmental factors play a role in IBD develop-
ment, mediated by changes in innate and adaptive
immune function, epithelial barrier function and
microbiome composition [4–6]. Genome-wide
association studies (GWASs) start to shed more light
on these processes, and the application of high
throughput methods to analyze the expression of
many factors involved in IBD pathogenesis will
further improve our knowledge about IBD.
Based on cytokine profiles observed in IBD
patients, Crohn’s disease is traditionally thought to
be mainly mediated by a Th1-cell response, and ulcer-
ative colitis by a Th2-like response [7
&
,8]. Recently, it
became clear that this separation is more nuanced.
Crohn’s disease seems to be mediated by a Th1
response combined with a Th17 response, both caus-
ing tissue injury. In ulcerative colitis the response is
mediated by cytokines similar to those observed in a
Th2 response, mediated by NK-cells causing direct
and indirect tissue injury [8]. Evidence for the
involvement of T-cells, NK-cells and dendritic cells
in IBD pathophysiologyhas been confirmed in a large
recent GWAS [9
&&
]. Other components of the adap-
tive immune response play a role in IBD pathogenesis
as well. For example, bacterial recognition and
antigen loading of bacterial fragments onto MHC
molecules through the process of autophagy appear
to be important [10]. In addition, increased expres-
sion of adhesion molecules, chemokines and mRNA
involved in oxidative stress is observed in IBD
patients [7
&
], which indicates important roles for cell
trafficking and responses to tissue injury in disease
mechanisms.
HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Originally, hematopoietic stem cell transplanta-
tion (HSCT) was used as treatment for differentCopyright © Lippincott Williams & Wilkins. Unau
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immune conditions emerged after the observation
of positive effects in animal models. This concept
was supported by the observation that human auto-
immune diseases improved in patients undergoing
HSCT for other indications [2
&&
]. The HSCT pro-
cedure starts with mobilization of HSCs from the
bone marrow into the peripheral blood and harvest-
ing of those HSCs. Before the transplantation, the
patient undergoes a preparative treatment that
ablates the immune system, after which the HSCs
are administered intravenously [1]. The rationale
behind HSCT for autoimmune and chronic
inflammatory diseases, including IBD, is that this
procedure can ‘reset’ the immune system. The
preparative chemotherapy eliminates the immune
system, including autoreactive T-cells. By sub-
sequently performing autologous HSCT, hemato-
poietic precursors will generate a new tolerant
T-cell population, mediated by T-cell selection pro-
cesses in the thymus. This concept is supported by
two studies analyzing immune reconstitution after
autologous HSCT in patients with multiple sclerosis
[11] and systemic lupus erythematosus [12], which
showed increased thymic output after HSCT
with the development of a new and diverse T-cell
repertoire. Allogeneic transplantation offers the
additional benefit of removing the genetic sus-
ceptibility of the immune system, and evidence
for an additional beneficial effect of graft-versus-
autoimmunity has been described as well. Alloge-
neic HSCT, however, is associated with higher
complication and mortality rates and is therefore
being discouraged as treatment for autoimmune
diseases in current guidelines [2
&&
]. In IBD patients
with severe refractory disease that are not eligible for
surgery, autologous HSCT can be considered, using a
relatively low-dose chemotherapy (compared with
the regimens used in cancer treatment), usually
consisting of cyclophosphamide and anti thymo-
cyte globulin antibodies.
Currently, the most extensive experience in
HSCT for IBD has been published by Burt et al.
[13]. Twenty-four Crohn’s disease patients with
severe disease refractory to conventional therapy,
including anti-TNFa antibodies, received autolo-
gous HSCT. Of these, 91% stayed in remission for
1 year after HSCT, 57% for 3 years and 19% for 5
years [13]. Recently, another group reported similar
outcomes in a cohort of 10 refractory Crohn’s
disease patients, with remission rates of 80% after
1 year, 40% after 3 years, and 30% after 5 years. Also,
out of four patients that suffered from fistula, three
experienced closure of the fistula tract [14
&
]. In
our experience, two refractory Crohn’s disease
patients underwent autologous HSCT. Both patientsthorized reproduction of this article is prohibited.
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Inflammatory bowel diseaseachieved disease remission after the transplantation
procedure. One patient restarted medication after
12 months, and no luminal relapse was observed
during the follow-up period of 6 years. The other
patient restarted medication after 6 months,
relapsed only after 5 years, and achieved remission
again after switching medication [15]. These results
are promising, but for a definite assessment of the
efficacy of HSCT for IBD, the results of a randomized
controlled phase III trial are warranted. Currently, a
multicenter, prospective, randomized phase III
study is being performed that analyzes the effect
of autologous HSCT vs. stem cell mobilization
alone in refractory Crohn’s disease patients
(ASTIC-trial) (http://www.nottingham.ac.uk/icr/
astic). All patients have been recruited and prelimi-
nary data were presented recently. A median fall in
the Crohn’s disease activity index of 162 was
observed in the HSCT group, compared with 82 in
the group receiving mobilization alone. Patients that
received HSCT also considerably improved endo-
scopically, while no improvement was seen in the
control group. Though the results are preliminary,
autologous HSCT seems to be an effective treatment
for refractory Crohn’s disease. Serious adverse events
in both groups were common though, raising con-
cerns about safety [16
&&
].
A recent analysis assessing safety of HSCT in
70 patients with autoimmune diseases in the United
Kingdom showed an overall survival of 87% after
1 year and 65% after 5 years following allogeneic
HSCT. For autologous HSCT the survival was 85% at
1 year and 78% after 5 years. Age was strongly
correlated with survival, with the highest survival
in the 18–39 year age group (5 year survival 95%).
The underlying autoimmune disease affected the
outcome as well. The most common cause of death
was infection after both autologous and allogeneic
HSCT [17]. Another analysis of 900 autoimmune
patients undergoing HSCT showed a 5-year survival
rate of 85%. Half of the deaths were related to
transplantation, with the main cause of death being
infection. Outcomes were interestingly not depend-
ent on the type of conditioning regimen, but were
strongly correlated with the transplantation center
[18]. Because of the inherent risks associated with
HSCT, this therapy is only considered in severe
refractory cases, in which the potential benefit
weighs out against the risks. Currently, all trials have
focused on severe refractory Crohn’s disease
patients. No trials analyzing HSCT for ulcerative
colitis patients have been published yet, though
improvement of ulcerative colitis after both
allogeneic and autologous HSCT has been described
in ulcerative colitis patients undergoing HSCT
for other indications [19,20] and in a case ofopyright © Lippincott Williams & Wilkins. Unautho
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colitis [21].
To increase the applicability of HSCT for IBD,
improvement of safety is a top priority. As men-
tioned above, infectious complications are the most
common cause of treatment-related mortality due
to prolonged lymphopenia after HSCT. To shorten
the lymphopenic period after HSCT, different
approaches have been sought to accelerate immune
reconstitution after HSCT. In this context admi-
nistration of keratinocyte growth factor, growth
hormone and cytokines such as IL-2 and IL-7 has
been tested, with the goal of stimulating thymic
function and promoting lymphocyte survival
[22
&
,23
&
]. Also, adoptive transfer of specific T cells
[22
&
], and ex-vivo expansion of hematopoietic pre-
cursor cells [24,25,26
&
] are being explored to
improve safety. To improve efficacy, allogeneic
HSCT might be considered because the genetic
susceptibility of the immune system will be perma-
nently removed. Currently, a phase I trial assessing
toxicity and efficacy of allogeneic HSCT in Crohn’s
disease is being performed (http://www.clinical
trials.gov/ct2/show/NCT01288053).MESENCHYMAL STEM CELL THERAPY
MSCs, also called mesenchymal stromal cells, are a
heterogeneous group of stromal cells that have the
capability to differentiate into different mesenchy-
mal cell types and also exert immunosuppressive
functions. The combination of those two properties
makes the application of MSCs for tissue regener-
ation in inflammation-induced tissue injury a pro-
mising approach [3
&
]. MSCs are isolated from
stromal tissues based on their plastic adherence or
using specific surface markers [27]. Originally, MSC
research mainly focused on bone marrow-derived
MSCs (bm-MSCs). Alternatively, adipose tissue-
derived MSCs (ad-MSCs) can be isolated in high
frequencies from liposuction aspirates. The immu-
nophenotypes of ad-MSCs and bm-MSCs are more
than 90% identical, and ad-MSCs have a similar or
even enhanced immunosuppressive capacity com-
pared with bm-MSCs. Since MSCs in liposuction
aspirates are abundant, these cells can be used
clinically without ex-vivo expansion, in contrast
to bm-MSCs [28]. These properties mean that
ad-MSCs can be a valuable, more accessible, and
safe alternative to bm-MSCs.
In-vitro experiments have shown that MSCs are
able to interfere with components of both innate
and adaptive immune system. In the adaptive
immune system MSCs interfere with complement,
toll-like receptor signaling, macrophages, dendritic
cells, neutrophils and NK cells. In the adaptiverized reproduction of this article is prohibited.
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Stem cell therapy in inflammatory bowel disease van Deen et al.immune system, MSCs inhibit T-cell function, shift
T-cell balance and induce Treg cells. Inhibition of
B-cells has also been suggested in different studies
[29
&&
]. Before MSCs exert their immunosuppressive
function they require priming by pro-inflammatory
cytokines such as IFNg, TNFa and IL-1b. The immu-
nosuppressive effect that MSCs exert is mainly medi-
ated by soluble factors, but certain MSC-immune
cell interactions are contact-dependent [29
&&
].
Depending on the environment, MSCs can also
acquire pro-inflammatory properties [29
&&
,30
&
]. This
suggests that in the event of active infection,
MSCs might adopt a pro-inflammatory phenotype,
whereas in the case of an exaggerated inflammatory
response they will adopt an immunosuppressive
phenotype (Fig. 1). In different mouse models, a
positive effect of MSCs on experimental colitis is
shown as well. MSCs are infused either intra-
venously [31] or intraperitoneally [32,33] and
improve experimental colitis [31–33]. Our group
confirmed in vivo that IFNg-stimulated MSCs have
enhanced immunosuppressive functions by show-
ing reduced weight loss and lower histology scores
in two mouse models of colitis [33].
The first clinical successes with MSCs in inflam-
matory conditions were achieved in severe graft
versus host disease (GvHD). Several encouraging
results are obtained from clinical trials assessing
allogeneic MSCs for the treatment [34] and preven-
tion [35] of GvHD. Significant improvement of
severe GvHD was observed after administration ofCopyright © Lippincott Williams & Wilkins. Unau
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FIGURE 1. The two faces of mesenchymal stem cells (MSCs).
acquire an immune suppressive phenotype (left), suppressing amo
cells, and neutrophils. Under influence of an active infection, MSC
response and support pathogen clearance (right).
0267-1379  2013 Wolters Kluwer Health | Lippincott Williams & WilkMSCs compared to a control population [34], and
significantly fewer patients developed severe GvHD
after HSCT if MSCs were co-infused simultaneously
with the graft [35]. However, a randomized placebo-
controlled trial using industrially manufactured
allogeneic MSCs for GvHD treatment failed to show
a durable complete response for 28 days [36].
In the IBD field MSCs have been tested in
clinical trials for two indications, namely fistulizing
disease and luminal disease (Table 1) [37,38,39
&
,
40,41
&
,42
&
,43,44
&
,45
&
]. For luminal disease, the
rationale for the use of MSCs lies mainly in their
immunosuppressive capacity. In fistulizing disease,
the differentiation potential of MSCs is thought to
be of crucial importance as well to achieve fistula
tract closure. Several phase I/II trials have been
performed analyzing ad-MSCs for fistulizing disease,
using autologous [37,38,39
&
] or allogeneic [41
&
]
MSCs. One study evaluated the effect of bm-MSCs
on fistulizing Crohn’s disease [40]. The outcomes of
these trials are promising and the procedure seems
safe. A placebo-controlled trial evaluating the
efficacy of ad-MSCs compared with fibrin glue for
Crohn’s disease related and unrelated fistula found
70% healing in the treatment group, which was
four-fold higher than in the control group [38]. After
4 years of follow-up, however, only 33% remained
healed in the treatment group vs. 15% in the control
group [39
&
]. Recently the results of the FATT1 trial
were published, a phase III randomized controlled
trial assessing the efficacy of autologous ad-MSCs forthorized reproduction of this article is prohibited.
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Table 1. Published trials analyzing mesenchymal stem cell treatment for different fistulizing diseases and for
luminal inflammatory bowel disease
Indication MSC source Results
Fistulizing disease
Garcia-Olmo et al. [37] CD ad-MSC (auto) 6/8 healed, 2/8 improvement (8 wk)
Garcia-Olmo et al. [38]
CD and non-CD ad-MSC (auto)
71% ad-MSC $ 16% fibrin glue (8 wk)
Guadalajara [39&] 33% ad-MSC $ 15% fibrin glue (4yr)
Ciccocioppo et al. [40] CD bm-MSC (auto) 7/10 healed, 3/10 improved (1 yr)
de la Portilla et al. [41&] CD ad-MSC (allo) 14/20 closure (24 wk)
Herreros et al. [42&] Non-CD ad-MSC (auto) 42% ad-MSC $ 39% fibrin glue (24 wk)
Luminal IBD
Duijvestein et al. [43] CD bm-MSC (auto) Improvement 3/10, no remission
Liang et al. [44&] CD and UC bm/uc-MSC (allo) Remission 5/8
Forbes et al. [45&] CD bm-MSC Improvement 12/14, remission 8/14
ad-MSC, adipose tissue derived MSC; allo, allogeneic; auto, autologous; bm-MSC, bone marrow derived MSC; CD, Crohn’s disease; IBD, inflammatory bowel
disease; UC, ulcerative colitis; uc-MSC, umbilical cord derived MSC; wk, week; yr, year.
Inflammatory bowel diseaseperianal fistulas that were not related to Crohn’s
disease. Disappointingly, no significant difference
between the different treatment groups was shown
[42
&
]. To assess the efficacy of MSCs for Crohn’s
disease-related fistula, the ADMIRE-Crohn’s disease
study is currently being performed (http://www.
clinicaltrials.gov/ct2/show/NCT01541579). Several
trials for luminal Crohn’s disease have been per-
formed as well. A phase I trial we performed using
autologous bm-MSCs for luminal Crohn’s disease,
designed primarily for safety and feasibility, showed
improvement in three out of 10 patients, of which
none achieved remission [43]. Another group
treated four Crohn’s disease and three ulcerative
colitis patients with allogeneic MSCs. Five patients
achieved remission, of which two stayed in remis-
sion for over 2 years [44
&
]. Recently, preliminary
results of a phase II trial analyzing the use of
allogeneic bm-MSCs for refractory luminal Crohn’s
disease were presented. Improvement was observed
in 12 out of 14 included patients, remission in eight
and endoscopic improvement in seven [45
&
]. These
studies were not designed to assess efficacy, but did
demonstrate safety of intravenous (i.v.) infusion of
MSCs. This notion is supported by a recent meta-
analysis analyzing safety of i.v. MSC infusion for
many different indications. MSC infusion is
associated with a transient fever, but not with acute
infusion toxicity, organ system complications,
infection, malignancies, or death [46
&&
].
MSC therapy for IBD represents a promising
strategy but results have been inconsistent. The
comparison between different studies is challenging
because different isolation, selection and expansion
protocols are being utilized. The development ofopyright © Lippincott Williams & Wilkins. Unautho
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reproducible and consistent results. To improve
efficacy, robust priming of MSCs is probably of
crucial importance. In the currently performed
trials, no priming of MSCs has been performed.
Therefore, determining the optimal protocols to
prime MSCs before administration might improve
the clinical results. Second, MSCs are a hetero-
geneous cell population and it has been described
that different subsets of these cells have different
functional capacities [27]. Identifying and isolating
a subpopulation of MSCs with enhanced immu-
nosuppressive properties might be a promising
strategy to improve clinical efficacy. Lastly, notable
differences in immunosuppressive capacity between
MSCs from different donors have been found [47
&
].
Therefore, a careful selection process of the right
donor might be favorable for outcomes too.EMERGING STEM CELL THERAPIES
Several other stem cells have been explored in
preclinical settings as well. Induced pluripotent
stem cells (iPSCs) are pluripotent cells derived
from terminally differentiated cells by dedifferen-
tiation. The generation of iPSCs creates the possi-
bility of generating tissue specific cells, but also
HSCs or MSCs [48]. Intestinal stem cells also carry a
strong therapeutic potential to enhance mucosal
healing. After administration of ex-vivo expanded
colonic stem cells, engraftment of the cells in, and
healing of, colonic mucosa has been shown in
mice [49
&&
]. Lastly, specific cellular therapies are
offering clinical potential as well. For example,
administration of ex-vivo expanded Treg cellsrized reproduction of this article is prohibited.
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model [50].CONCLUSION
Treatment of refractory IBD patients remains a
challenge. HSCT and MSC therapy are both pro-
mising strategies to improve disease control in this
patient group. HSCT is effective, but is also accom-
panied by a high complication rate. Improving
safety will increase the applicability of this therapy
in IBD patients. MSC therapy seems promising but
results have been inconsistent. Optimization of this
therapeutic strategy is therefore strongly warranted.
For both therapies results of phase III studies for IBD
are still lacking but are expected in the near future
and will shed more light on the efficacy. Next to
those two clinically investigated therapies, several
other stem cell and cellular therapies are being
explored in preclinical settings. Some of those have
a promising clinical potential, but further research
needs to be performed to explore safety and feasi-
bility of those approaches.
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